Proctosedyl Ointment *
Status:No Recent Update
Legal Category:Product subject to medical prescription which may not be renewed (A)
*Additional information is available within the SPC or upon request to the company
Summary of Product Characteristics last updated on medicines.ie:4/12/2017
Each gram of ointment contains 5mg of Hydrocortisone, 5mg of Cinchocaine Hydrochloride, 10mg Aesculin and 10mg Framycetin Sulphate.
Excipients – Contains Wool Fat 10%w/w
For a full list of excipients, see section 6.1.
Yellow white, translucent, homogeneous, ointment.
4.1 Therapeutic indications
In the local management of pain, pruritus and inflammation associated with internal or external haemorrhoids, and such haemorrhoidal complications as fissures, proctitis, perianal eczema, and post1-operative states.
4.2 Posology and method of administration
Application to external surface or by means of the cannula into the rectum, twice daily and after each bowel movement. Treatment should last for a week.
Topical, Intrarectal and Perianal
1. Use in the presence of untreated infections of viral, bacterial, tuberculous, parasitic or fungal origin.
2. Use in patients hypersensitive to the active ingredient or any of the excipients.
4.4 Special warnings and precautions for use
Continuous treatment for longer than three weeks should be avoided in patients under the age of three years because of the possibility of adrenocortical suppression and growth retardation.
Continuous application without interruption will result in local atrophy of the skin, striae, and superficial vascular dilation.
Prolonged use of an anti-infective may result in the development of super-infection due to organisms, including fungi, resistant to that anti-infective.
May cause local skin reactions (e.g. contact dermatitis).
Before prescribing the product any potential malignancies should be excluded.
Pheochromocytoma crisis, which can be fatal, has been reported after administration of corticosteroids. Corticosteroids should only be administered to patients with suspected or identified pheochromocytoma after an appropriate risk/benefit evaluation (see section 4.8)
Visual disturbance may be reported with systemic and topical corticosteroid use. If a patient presents with symptoms such as blurred vision or other visual disturbances, the patient should be considered for referral to an ophthalmologist for evaluation of possible causes which may include cataract, glaucoma or rare diseases such as central serous chorioretinopathy (CSCR) which have been reported after use of systemic and topical corticosteroids.
4.5 Interaction with other medicinal products and other forms of interaction
Co-treatment with CYP3A inhibitors, including cobicistat-containing products, is expected to increase the risk of systemic side-effects. The combination should be avoided unless the benefit outweighs the increased risk of systemic corticosteroid side-effects, in which case patients should be monitored for systemic corticosteroid side-effects.
4.6 Pregnancy and lactation
In pregnant animals, administration of corticosteroids can cause abnormalities of foetal development. The relevance of this finding to human beings has not been established.
Hydrocortisone may pass into human breast milk..
This product should not be used in pregnancy or lactation unless considered essential by the physician.
4.7 Effects on ability to drive and use machines
4.8 Undesirable effects
Itching, pain or rash may develop around the back passage.
Skin and subcutaneous disorders:
Frequency not known: Urticaria, contact dermatitis, rash.
Frequency not known: Pheochromocytoma crisis, adrenal suppression.
Vision blurred (see also section 4.4).
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via HPRA Pharmacovigilance, Earlsfort Terrace, IRL - Dublin 2; Tel: +353 1 6764971; Fax: +353 1 6762517. Website: www.hpra.ie; E-mail: firstname.lastname@example.org.
In the rare event of overdosage, supportive and symptomatic therapy is indicated.
5.1 Pharmacodynamic properties
ATC Code: C05A.
A combination of a glucocorticoid, local anaesthetic and antibacterial.
5.2 Pharmacokinetic properties
5.3 Preclinical safety data
6.1 List of excipients
Wool fat (lanolin)
White soft paraffin.
6.3 Shelf life
Unopened - 3 years
In use shelf life - 4 weeks
6.4 Special precautions for storage
Do not store above 25°C.
6.5 Nature and contents of container
Aluminium tubes internally lacquered with cannula treatment. Pack sizes are 15g and 30g. Each tube is accompanied by a cannula attachment.
Not all pack sizes are marketed.
6.6 Special precautions for disposal and other handling
No special requirements.
sanofi-aventis Ireland Ltd. T/A SANOFI
Citywest Business Campus
1st April 1978/25th November 2009.